Pohl G, Kaplan L, Einarsson M, Wallén P, Jörnvall H
FEBS Lett. 1984 Mar 12;168(1):29-32. doi: 10.1016/0014-5793(84)80200-8.
Tissue plasminogen activator purified from human uterine tissue exhibits differences in N-terminal starting positions in relation to the melanoma cell plasminogen activator usually studied. A new starting position is compatible with an additional N-terminal processing apart from those already known. Like the melanoma activator, the uterine activator was found to yield protein chains starting at either of two positions. One of these was identical between uterine and melanoma activators, whereas the other was unique in each case. The most abundant starting position for the uterine preparation was at a valine residue, apparently from cleavage of a Gln-Val bond, and corresponding to Val-7 of the longest form of the melanoma activator chain.
从人子宫组织中纯化得到的组织型纤溶酶原激活剂,与通常研究的黑色素瘤细胞纤溶酶原激活剂相比,在N端起始位置上存在差异。一个新的起始位置与除已知的那些之外的额外N端加工过程相符。与黑色素瘤激活剂一样,发现子宫激活剂产生的蛋白质链起始于两个位置中的任何一个。其中一个在子宫和黑色素瘤激活剂中是相同的,而另一个在每种情况下都是独特的。子宫制剂最丰富的起始位置是在一个缬氨酸残基处,显然是由Gln-Val键的裂解产生的,并且对应于黑色素瘤激活剂链最长形式的Val-7。